For decades, HIV prevention has hinged on daily pills—a regimen that works when people can stick to it, but often falls short where access, stigma, or barriers get in the way. Now the European Commission has approved lenacapavir, a twice-a-year injection branded as Yeytuo, for pre-exposure prophylaxis (PrEP) across the EU, Norway, Iceland, and Liechtenstein, according to Reuters. This is the first time the region has embraced a long-acting PrEP option with such infrequent dosing. The approval, hailed as a “game changer,” comes after regulators at the European Medicines Agency gave it the green light in July.
Prevention redesigned for real life
Lenacapavir’s approval could turn prevention from a daily hassle into a twice-yearly check-in, and that matters a lot. Clinical trials showed that when given correctly, the jab was nearly 100 percent effective in preventing HIV infection. That kind of efficacy is unprecedented and offers real hope for communities where stigma, unpredictable schedules, or stigma make daily PrEP unrealistic.
When we look at populations already hardest hit by HIV, such as trans people, sex workers, LGBTQ+ individuals, or people in unstable housing, this injection opens up freedom. It lets prevention fit into life rather than life fitting into prevention. No more counting pills or planning ahead; a quick clinical visit, and you’re protected for months.
The European stamp of approval means Yeytuo is now on offer in 30 countries, but rollout won’t happen instantly. Gilead still needs to negotiate drug pricing with each national health system, and high list prices—in the U.S., coverage began at just under $28,000 a year—mean these discussions could affect how fast and easily people can access it. Still, the World Health Organization has already endorsed the jab as a critical addition to HIV prevention options worldwide, and Gilead has committed to partnering with the Global Fund to supply the drug, royalty-free, in lower-income countries.
A hinge point for global HIV strategy
This approval couldn’t have come at a more important moment. Global HIV cases continue at around 1.3 million new infections per year, with gaps in PrEP access, inconsistent adherence, and rising resistance threatening to stall progress. In Europe, diagnoses rose nearly 12 percent between 2022 and 2023. So, lenacapavir’s authorization arrives as both a needed innovation and a statement that prevention still matters.
What’s more, it sets a precedent for public health: we’re now seeing real interest in developing long-acting formulations for prevention. Decades after HIV was first diagnosed, this jab is the first vaccine-like tool available, and regulators fast-tracked its approval because of the opportunity to shift the needle in the epidemic.
The hurdles ahead, and hope in the details
There’s no magic wand here. Global access still depends on cost, distribution, and the political will to fund prevention. The WHO recommends the injection, and Gilead has licensed production to generics in 120 low-income countries, but major middle-income markets like Latin America are excluded for now. That patchwork rollout could reinforce health disparities rather than erase them.
Then there’s medical protocol. The jab is highly effective, but only when administered correctly: two starter tablets followed by six-month injections. Health systems need infrastructure, training, and engagement strategies to make it seamless. That raises questions about uptake, adherence, and whether clinics in rural or marginalized communities can deliver it equitably.
And we can’t ignore scepticism or stigma toward HIV prevention. Rolling out a biomedical solution is powerful, but it must be paired with education, community outreach, and funding for diagnostics and support services.
Still, this is a real opportunity. If done right, this jab could reduce HIV transmission more efficiently than anything that came before it. Ending the epidemic is still a ways off, but doubling down on prevention, with innovative tools like this, could mean the target is closer than we think.
Yeytuo’s approval is more than a regulatory win. It’s a reminder that prevention deserves the urgency we often reserve for cures. And it could be the turning point in making HIV prevention simpler, smarter, and more compassionate for everyone.